Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Real-world Danish registry data show that biologic drug survival in psoriasis differs between biologic-naive and ...

Arrowhead Pharmaceuticals disclosed that its gene-silencing candidates helped people with obesity lose fat, very early ...

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

Danish dermatology specialist Leo Pharma and its CEO Christophe Bourdon came to San Francisco to attend the J.P. Morgan ...

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...

Two patients present with rash eruptions on different parts of the body. Can you correctly identify each case?

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The ...

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...